Unfortunately, the negative results of the phase III ENHANCE clinical trial (NCT04313881) that failed to confirm the exciting results from phase I and II data in patients with TP53 mutations treated with magrolimab and azacytidine emphasize the difficulty in treating this subset of MDS patients. This evidence concerns the gene TP53 and myelodysplastic syndrome.